PURPOSE: The usefulness and prognostic impact of a pretherapeutic clinical staging is still a matter of discussion. However, a pretherapeutic estimation of the prognosis would be essential to adjust the patient's therapy. Our aim was to compare clinical and histopathological staging and to analyze the predictive value of routine clinical staging and its significance for the individualization of treatment. PATIENTS AND METHODS: We analyzed the data of 368 patients treated with gastric cancer in the University of Heidelberg, Department of Surgery, from January 2001 to June 2009. Pretherapeutic parameters including sex, age, cTNM, grading, Laurén classification, tumor localization, as well as posttherapeutic parameters were analyzed, and their impact for survival was evaluated. Follow-up data was obtained for all patients (2.17% lost to follow-up). RESULTS: The overall accuracy was 64.1% for pT category, 54.5% for pN category, and 80.3% for M category for the primary resected patients. For the patients treated neoadjuvantly, the overall accuracy was 21.8% for the pT category, 58.0% for the pN category, and 80.0% for the M category. The prognosis was associated to the age (p = 0.017), tumor localization (p < 0.001), grading (p = 0.041), cT category (p < 0.001), cN category (p < 0.001), and cM category (p = 0.001). The multivariate analysis, including pre- and postoperative factors, revealed tumor localization (p = 0.002), cN category (p = 0.019), and metastatic lymph node rate (p < 0.001) as independent prognostic factors. CONCLUSION: The accordance between clinical and histopathological staging is limited, but nevertheless pretherapeutic parameters have a high prognostic impact and could be used for individualized therapy planning. The relevant pretherapeutic prognostic factors can all be determined by routine clinical staging including CT and endoscopy. Consequently pretherapeutic prognostic evaluation and therapy planning seem to be feasible with routine staging methods.
PURPOSE: The usefulness and prognostic impact of a pretherapeutic clinical staging is still a matter of discussion. However, a pretherapeutic estimation of the prognosis would be essential to adjust the patient's therapy. Our aim was to compare clinical and histopathological staging and to analyze the predictive value of routine clinical staging and its significance for the individualization of treatment. PATIENTS AND METHODS: We analyzed the data of 368 patients treated with gastric cancer in the University of Heidelberg, Department of Surgery, from January 2001 to June 2009. Pretherapeutic parameters including sex, age, cTNM, grading, Laurén classification, tumor localization, as well as posttherapeutic parameters were analyzed, and their impact for survival was evaluated. Follow-up data was obtained for all patients (2.17% lost to follow-up). RESULTS: The overall accuracy was 64.1% for pT category, 54.5% for pN category, and 80.3% for M category for the primary resected patients. For the patients treated neoadjuvantly, the overall accuracy was 21.8% for the pT category, 58.0% for the pN category, and 80.0% for the M category. The prognosis was associated to the age (p = 0.017), tumor localization (p < 0.001), grading (p = 0.041), cT category (p < 0.001), cN category (p < 0.001), and cM category (p = 0.001). The multivariate analysis, including pre- and postoperative factors, revealed tumor localization (p = 0.002), cN category (p = 0.019), and metastatic lymph node rate (p < 0.001) as independent prognostic factors. CONCLUSION: The accordance between clinical and histopathological staging is limited, but nevertheless pretherapeutic parameters have a high prognostic impact and could be used for individualized therapy planning. The relevant pretherapeutic prognostic factors can all be determined by routine clinical staging including CT and endoscopy. Consequently pretherapeutic prognostic evaluation and therapy planning seem to be feasible with routine staging methods.
Authors: J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus Journal: N Engl J Med Date: 1999-03-25 Impact factor: 91.245
Authors: E Bollschweiler; K Boettcher; A H Hoelscher; M Sasako; T Kinoshita; K Maruyama; J R Siewert Journal: Br J Surg Date: 1992-02 Impact factor: 6.939
Authors: Sook Ryun Park; Min Ju Kim; Keun Won Ryu; Jun Ho Lee; Jong Seok Lee; Byung-Ho Nam; Il Ju Choi; Young-Woo Kim Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: Andrew P Barbour; Nabil P Rizk; Mithat Gonen; Laura Tang; Manjit S Bains; Valerie W Rusch; Daniel G Coit; Murray F Brennan Journal: Ann Surg Date: 2007-07 Impact factor: 12.969
Authors: Hendrik Manner; Thomas Rabenstein; Andrea May; Oliver Pech; Liebwin Gossner; Daniel Werk; Nicola Manner; Erwin Günter; Jürgen Pohl; Michael Vieth; Manfred Stolte; Christian Ell Journal: Am J Gastroenterol Date: 2009-02-17 Impact factor: 10.864
Authors: Ulrike Heger; Franz Bader; Florian Lordick; Maria Burian; Rupert Langer; Martin Dobritz; Susanne Blank; Thomas Bruckner; Karen Becker; Ken Herrmann; Jörg-Rüdiger Siewert; Katja Ott Journal: Gastric Cancer Date: 2013-09-01 Impact factor: 7.370
Authors: Kunning Wang; Enxiao Li; Rita A Busuttil; Joseph C Kong; Sharon Pattison; Joseph J Y Sung; Jun Yu; Emad M El-Omar; Julie A Simpson; Alex Boussioutas Journal: Ther Adv Med Oncol Date: 2020-07-23 Impact factor: 8.168
Authors: S Blank; A Stange; L Sisic; W Roth; L Grenacher; F Sterzing; M Burian; D Jäger; M Büchler; K Ott Journal: Langenbecks Arch Surg Date: 2012-12-07 Impact factor: 3.445
Authors: T Schmidt; L Sicic; S Blank; K Becker; W Weichert; T Bruckner; T Parakonthun; R Langer; M W Büchler; J-R Siewert; F Lordick; K Ott Journal: Br J Cancer Date: 2014-02-25 Impact factor: 7.640
Authors: Susanne Blank; Phillip Knebel; Georg-Martin Haag; Thomas Bruckner; Ulla Klaiber; Maria Burian; Anja Schaible; Leila Sisic; Thomas Schmidt; Markus K Diener; Katja Ott Journal: Pilot Feasibility Stud Date: 2016-04-04